Switch theme
Sign up to access all valuation multiples
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
2007
53
Last FY Revenue $9.0M
Last FY EBITDA -$1.7M
$69.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Pangaea Oncology achieved revenue of $9.0M and an EBITDA of -$1.7M.
Pangaea Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pangaea Oncology valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $9.0M | XXX | XXX | XXX |
| Gross Profit | XXX | $8.7M | XXX | XXX | XXX |
| Gross Margin | XXX | 97% | XXX | XXX | XXX |
| EBITDA | XXX | -$1.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -19% | XXX | XXX | XXX |
| EBIT | XXX | -$3.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | -34% | XXX | XXX | XXX |
| Net Profit | XXX | -$5.2M | XXX | XXX | XXX |
| Net Margin | XXX | -58% | XXX | XXX | XXX |
| Net Debt | XXX | $4.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pangaea Oncology's stock price is EUR 2 (or $2).
Pangaea Oncology has current market cap of EUR 58.9M (or $66.2M), and EV of EUR 62.0M (or $69.6M).
See Pangaea Oncology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $69.6M | $66.2M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pangaea Oncology has market cap of $66.2M and EV of $69.6M.
Pangaea Oncology's trades at 7.8x EV/Revenue multiple, and -39.8x EV/EBITDA.
Equity research analysts estimate Pangaea Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pangaea Oncology's P/E ratio is not available.
See valuation multiples for Pangaea Oncology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $66.2M | XXX | $66.2M | XXX | XXX | XXX |
| EV (current) | $69.6M | XXX | $69.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 7.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -39.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -22.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -12.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -23.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPangaea Oncology's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Pangaea Oncology's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pangaea Oncology's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pangaea Oncology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -19% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 131% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pangaea Oncology acquired XXX companies to date.
Last acquisition by Pangaea Oncology was XXXXXXXX, XXXXX XXXXX XXXXXX . Pangaea Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pangaea Oncology founded? | Pangaea Oncology was founded in 2007. |
| Where is Pangaea Oncology headquartered? | Pangaea Oncology is headquartered in Spain. |
| How many employees does Pangaea Oncology have? | As of today, Pangaea Oncology has 53 employees. |
| Is Pangaea Oncology publicy listed? | Yes, Pangaea Oncology is a public company listed on MAD. |
| What is the stock symbol of Pangaea Oncology? | Pangaea Oncology trades under PANG ticker. |
| When did Pangaea Oncology go public? | Pangaea Oncology went public in 2016. |
| Who are competitors of Pangaea Oncology? | Similar companies to Pangaea Oncology include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Pangaea Oncology? | Pangaea Oncology's current market cap is $66.2M |
| Is Pangaea Oncology profitable? | Yes, Pangaea Oncology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
